A federal judge in Pennsylvania has nixed the proposed $100 million settlement by one of the defendants named in the massive fen-phen and Redux diet-drug litigation, finding that the class action fell short of the strict rules that govern such "limited fund" settlements. The ruling by Senior U.S. District Judge Louis C. Bechtle means that Interneuron Pharmaceuticals Inc. must continue to defend itself against a slew of lawsuits in both state and federal courts.
September 29, 1999 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
A federal judge has nixed the proposed $100 million settlement by one of the defendants named in the massive fen-phen and Redux diet-drug litigation, finding that the class action fell short of the strict rules that govern such “limited fund” settlements.
The ruling by Senior U.S. District Judge Louis C. Bechtle means that Interneuron Pharmaceuticals Inc. must continue to defend itself against a slew of lawsuits in both the state and federal courts.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
